Medexus Pharmaceuticals Inc. (TSE:MDP) Receives C$5.49 Consensus PT from Analysts

Medexus Pharmaceuticals Inc. (TSE:MDP) has been assigned an average recommendation of “Buy” from the seven analysts that are currently covering the firm, Marketbeat reports. Two analysts have rated the stock with a hold recommendation, one has given a buy recommendation and four have assigned a strong buy recommendation to the company. The average 1 year price target among brokerages that have covered the stock in the last year is C$5.49.

A number of brokerages have recently weighed in on MDP. Stifel Canada lowered Medexus Pharmaceuticals from a “strong-buy” rating to a “hold” rating in a research note on Thursday, February 6th. Stifel Nicolaus downgraded Medexus Pharmaceuticals from a “buy” rating to a “hold” rating and decreased their target price for the stock from C$6.00 to C$3.45 in a report on Friday, February 7th. Ventum Financial lifted their target price on Medexus Pharmaceuticals from C$5.00 to C$6.25 and gave the stock a “buy” rating in a report on Thursday, January 30th. Leede Financial raised Medexus Pharmaceuticals from a “moderate buy” rating to a “strong-buy” rating in a report on Wednesday, January 22nd. Finally, Ventum Cap Mkts raised Medexus Pharmaceuticals to a “strong-buy” rating in a report on Friday, January 17th.

Medexus Pharmaceuticals Stock Performance

Shares of MDP stock opened at C$3.03 on Friday. Medexus Pharmaceuticals has a fifty-two week low of C$1.47 and a fifty-two week high of C$5.56. The firm has a market capitalization of C$67.84 million, a price-to-earnings ratio of 14.49 and a beta of 1.96. The stock’s 50-day simple moving average is C$3.58 and its 200-day simple moving average is C$2.88.

About Medexus Pharmaceuticals

Medexus Pharmaceuticals Inc operates as a specialty pharmaceutical company in Canada and the United States. The company focuses on the therapeutic areas comprising oncology, hematology, rheumatology, auto-immune diseases, allergy, and dermatology. Its primary products are IXINITY, an intravenous recombinant factor IX therapeutic for use in patients 12 years of age or older with hemophilia B; Rasuvo and Metoject, a formulation of methotrexate designed to treat rheumatoid arthritis and other auto-immune diseases; Rupall, a prescription allergy medication; and Gleolan, an optical imaging agent indicated in patients with glioma as an adjunct for the visualization of malignant tissue during surgery.